Pure Global
NCT06057051

Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

A Prospective, Multicenter Study of the Glaukos® iStent Infinite Trabecular Micro-Bypass System Model iS3 in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Glaukos Corporation·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Glaucoma
Drug/Device/Intervention
iStent Infinite
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Glaukos Corporation
Location
Cincinnati, United States of America
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2023
End date
Aug 01, 2027
Enrollment
245 participants
Primary outcome

Mean Diurnal Intraocular Pressure (IOP) 12-Month reduction ≥ 20% from Baseline

Summary

Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or
 phakic subjects with mild to moderate primary open angle glaucoma who have not failed
 conventional medical and surgical treatment

ICD-10 classifications
GlaucomaGlaucomaOther glaucomaGlaucoma, unspecifiedGlaucoma in diseases classified elsewhere
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06057051
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06057051 through Pure Global AI's free database. This phase not specified trial is sponsored by Glaukos Corporation and is currently Recruiting. The study focuses on Glaucoma. Target enrollment is 245 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.